Adrenocortical carcinoma pathophysiology

Adrenocortical carcinoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Adrenocortical carcinoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Staging
History and Symptoms
Physical Examination
Laboratory Findings
X Ray
MRI
CT
Ultrasound
Other Imaging Studies
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Radiation Therapy
Primary prevention
Secondary prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Study
Case #1
Adrenocortical carcinoma pathophysiology On the Web
Most recent articles
cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Adrenocortical carcinoma pathophysiology All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Adrenocortical carcinoma pathophysiology
CDC on Adrenocortical carcinoma pathophysiology
Adrenocortical carcinoma pathophysiology in the news
Blogs on Adrenocortical carcinoma pathophysiology
Hospitals Treating Adrenocortical carcinoma
Risk calculators and risk factors for Adrenocortical carcinoma pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2] Shivali Marketkar, M.B.B.S. [3] Ahmad Al Maradni, M.D. [4] Mohammed Abdelwahed M.D[5]

Overview

ACCs are typically large tumors upon clinical presentation, often measuring more than 6 cm in diameter. They are bilateral in 2% to 10% of cases. Genetic basis of ACC depends on genomic aberrations that contribute to neoplastic transformation of adrenocortical cells such as clonality, gene expression arrays, MicroRNAs, gene mutations, chromosomal aberrations, epigenetic changes. Intracellular signaling depends on suggested three pathways: IGF pathway, WNT signaling pathway, Vascular endothelial growth factor pathway. On gross pathology, a large tan-yellow surface with areas of hemorrhage and necrosis is a characteristic finding of adrenocortical carcinoma. On microscopic histopathological analysis, sheets of atypical cells with some resemblance to the cells of the normal adrenal cortex are a characteristic finding of adrenocortical carcinoma. ACC may be associated with other neoplastic syndromes such as Lynch syndrome, Beckwith-Wiedemann syndrome (BWS), Carney complex, Neurofibromatosis type 1.

Pathophysiology

• ACCs are typically large tumors upon clinical presentation, often measuring more than 6 cm in diameter.
• They are bilateral in 2% to 10% of cases.
• Metastases to the liver, lungs, or lymph nodes can be seen, and invasion of adjacent organs or venous extension into the renal vein and inferior vena cava may be present.
• Inferior vena cava invasion has been reported in 9% to 19% of cases at presentation.
• Due to the presence of internal hemorrhage, necrosis, and calcifications, these tumors tend to vary in appearance with frequent heterogeneous enhancement.

Spread can take several forms:  

• Direct invasion of the tumor capsule, invasion through the tumor capsule into extra-adrenal soft tissue
• Direct invasion of lymphatic vessels in and around the capsule and nearby blood vessels. Metastatic deposits are largely similar to the primary tumor

ACCs can be graded into low- and high-grade carcinoma groups based on their mitotic rates ( >20 mitoses per 50 high-power fields or <20 mitoses per 50 high-power fields)

• Mitotic rate was most closely associated with patient outcome.
• ACCs in children behave in a more indolent fashion compared with the adult, that is why there are so many pediatric ACCs but few pediatric deaths.

Genetics

The genetic dissection of ACC has revealed genomic aberrations that contribute to neoplastic transformation of adrenocortical cells:

1. Clonality

• ACCs initiate from monoclonal cell populations, suggesting that mutation events lead to clonal expansion and ultimate progression to cancer.
• Flow cytometry revealed aneuploidy in ACC. aneuploidy was observed in 75% of ACC.
• Assessment of aneuploidy with histopathological criteria in 7 of 9 adrenal tumors revealed a high correlation with Weiss score >3 (indicative of malignancy).
• No significant difference in overall survival was observed in patients with ACC exhibiting aneuploidy vs patients with ACC exhibiting diploid neoplasms.

2. Gene expression arrays

• An initial study identified elevated expression of genes involved in cell proliferation in ACC, such as IGF2, compared with increased expression of steroidogenic genes in ACA.

• Giordano et al identified unique transcriptionally activated (12q and 5q) and repressed (11q, 1p, and 17p) chromosomal regions in 33 ACCs vs 22 ACAs in a microarray study.

• Giordano et al (192) determined that ACC with high histological grade exhibited overexpression of cell cycle and functional aneuploidy genes and leading to the decreased survival of patients.

• Expression levels of BUB1B, PINK1, and DLG7 are identified in ACC.

3. MicroRNAs

• MicroRNAs are RNAs that are important in the regulation of gene expression.
• Numerous miRNAs have been identified in the regulation of various cellular processes such as proliferation, apoptosis, and differentiation.
• Dysregulation of miRNAs, such as overexpression or deletion, plays an important role in diseases.
• Mistargeting of the miRNAs, resulting in inhibition or activation of various oncogenes, tumor suppressors, and other factors important in tumor angiogenesis.
• The investigation identified 14 upregulated miRNAs and 9 downregulated miRNAs unique to ACC.
• Upregulated miRNAs in ACCs included miR-184, miR-210, and miR-503.
• Downregulated miRNAs included miR-214, miR-375, and miR-511.
• Levels of miR-184, miR-503, and miR-511 are able to distinguish benign from malignant adrenal tumors.
• MiR-483 was found to be significantly upregulated in pediatric ACCs.
• MiR-99a and miR-100 are bioinformatically predicted to target the 3- untranslated regions of IGF1R, RPTOR, and FRAP1 and were experimentally confirmed to target several components of the IGF-1 signaling pathway.

4. Gene mutations

• Targeted genetic analyses have identified somatic genetic changes in TP53, MEN1, IGF2, IGF2R, and p16.

• TP53 located on 17p13 is the most commonly mutated gene in ACC, present in at least one-third of ACCs.
• LOH in the gene encoding p16ink/ p14arf, CDKN2A is observed in a subset of ACCs. The tumor suppressor function of this gene has been established in multiple cancers. LOH of 11q13 has been identified in 83% of samples.
• MEN1 somatic mutations are unusual in sporadic ACC.
• The canonical Wnt pathway, the catenin gene, and CTNNB1 have been identified as activating point mutations in over 25% of both ACAs and ACCs in children and adults.

5. Chromosomal aberrations

• Comparative genomic hybridization(CGH) can identify structural chromosomal abnormalities within ACCs.

• ACCs showed complex chromosomal alterations. ACCs contained multiple chromosomal gains or losses with a mean of 10 events.

• The newest study confirmed increased alterations in ACC (44%) compared with ACAs (10%).

• In ACCs, the frequently observed chromosomal gains at 5, 7, 12, 16, 19, and 20 and losses at 13 and 22 were confirmed.

• The group identified genes within these regions with potential tumorigenic potential including fibroblast growth factor 4 (FGF4), cyclin-dependent kinase 4 (CDK4), and cyclin E1 (CCNE1). The study confirmed the diagnostic utility of 6 loci (5q, 7p, 11p, 13q, 16q, and 22q) in the differentiation of ACA and ACC.

• Genomic aberration at chromosomes 5, 12, and 17 are predicted to illustrate genes that initiate or maintain neoplastic transformation. Chromosome 17, specifically at 17p13, contains the well-known tumor suppressor gene TP53.

6. Epigenetic changes

• DNA methylation involves the addition of a methyl group to the cytosine pyrimidine ring or adenine purine ring.
• Dysregulation in this process is observed in tumor cells.
• A recent study revealed hypermethylation of promoters in ACC with correlation to poor survival and identified H19, PLAGL1, G0S2, and NDRG2 as silenced genes also provided evidence about the role of methylation in ACC tumorigenesis, particularly in the 11p15 locus containing IGF2 and H19.

Cellular signaling pathway

1. IGF pathway 2. WNT signaling pathway

• In the adult adrenal cortex, both IGF-1 and IGF-2 stimulate basal and ACTH-induced steroidogenesis.
• Overall, the main role of IGF-2 lies in fetal development and growth, whereas IGF-1 acts mainly postnatally.
• Prominent overexpression of IGF2 and alterations of the IGF2/H19 locus have been identified in sporadic ACC.
• The IGF2 gene is located on 11p15, which also includes a noncoding H19 gene and a cyclin-dependent kinase inhibitor, CDKN1C (p57KIP2) (216, 217), and 80% to 90% of all ACCs show very high IGF2 expression. Pediatric ACCs reveal a 20-fold overexpression of IGF2.
• Patients with high IGF2 expression levels and 11p15 LOH are associated with a 5-fold increased risk for recurrence and a shorter disease-free survival.
• loss of maternally expressed CDKN1C and H19 may contribute to adrenal tumorigenesis.
• The combination treatment of IGF-1R antagonists and mitotane resulted in a synergistic antiproliferative effect.

2. WNT signaling pathway

• The WNT/ catenin signaling pathway is a major developmental pathway in multiple organ systems, including the adrenal gland.

• The pathway is differentiated into 3 diverging signaling cascades dependent on signal conduction through:

• Catenin (canonical pathway)

• Ras homolog gene family small GTPase (planar cell polarity pathway)

• Phospholipase C (Wnt/ calcium pathway)

• Initial alterations of the WNT/ catenin system/pathway were identified in FAP.

• Recent examinations of adrenocortical tumors suggest that the WNT/ catenin signaling pathway plays an important role in sporadic adrenocortical tumorigenesis.

• Immunohistochemical analysis of 39 adrenal tumors revealed the accumulation of catenin in ACCs.

• Mutational analysis of the catenin gene CTNNB1 identified activating point mutations in ACCs.

• Inactivating mutations of AXIN2 (a component of the catenin destruction complex) have also been described in some adrenocortical tumors.

• Both nuclear catenin accumulation and activating CTNNB1 mutations are present in ACCs suggests that WNT activation is a part of ACA tumorigenesis.

3. Vascular endothelial growth factor

• The vascular endothelial growth factor (VEGF) is a chief regulator of cancer angiogenesis. Its effects are mediated through its receptors (VEGFRs).
• Elevated VEGF levels were identified in blood samples from ACC patients.
• Overexpression of VEGFR type 2 in ACC samples was observed by immunohistochemistry.
• The increased expression of VEGF correlates with the expression of IGF2.
• The pharmacological inhibition of VEGFRs is considered an attractive option for cancer treatment.

Hormones biosynthesis in adrenal cortex

• Cortisol is synthesized from cholesterol. Synthesis takes place in the zona fasciculata of the adrenal cortex.
• Aldosterone is produced in the zona glomerulosa
• Sex hormones are synthesized in in the zona reticularis
• The secretion of cortisol is controlled by hypothalamic-pituitary axis by the following mechanism:^[1][2]
  • Paraventricular nuclei in the hypothalamus release corticotropin-releasing hormone (CRH).
  • CRH is transferred to anterior pituitary via the portal veins.
  • CRH stimulates the activity of corticotrophs; cells that produce proopiomelanocortin (POMC) in the anterior pituitary.
  • Corticotrophs produce adrenocorticotropic hormone (ACTH) by the post-translational modification of POMC.
  • ACTH is drained into systemic circulation via the pituitary capillaries and stimulates the adrenal cortex (zona fasciculata) to produce cortisol.
  • Cortisol acts on hypothalamus and pituitary through a feedback mechanism to regulate the secretion of CRH and ACTH.

source: By David Richfield (User:Slashme) and Mikael Häggström. Derived from previous version by Hoffmeier and Settersr.In external use, this diagram may be cited as:Häggström M, Richfield D (2014). "Diagram of the pathways of human steroidogenesis". Wikiversity Journal of Medicine 1 (1). DOI:10.15347/wjm/2014.005. ISSN 20018762. - Self-made using bkchem and inkscape, CC BY-SA 3.0, https://commons.wikimedia.org/w/index.php?curid=6355511

Associated Conditions

Associated diseases with adrenocortical carcinoma are:

• Lynch syndrome
• Beckwith-Wiedemann syndrome (BWS)
• Carney complex
• Neurofibromatosis type 1
• Multiple endocrine neoplasia type1 (MEN1)

Gross Pathology

• On gross pathology, adrenocortical carcinomas are often large (>5 cm in largest diameter), with a tan-yellow cut surface and areas of hemorrhage and necrosis.
• Their cut surface ranges from brown to orange to yellow depending on the lipid content of their cells. Necrosis is almost always present.
• Typical ACC with a hypercellular population of cells with the earliest form of tumor necrosis.
• A typical ACC with a solid growth pattern and abundant eosinophilic cytoplasm with focal clear areas, consistent with lipid.

A large adrenal cortical carcinoma resected from a 27-year-old woman. The tumor measured 17 cm in diameter and invaded kidney and spleen which necessitated en bloc removal of these organs with the tumor.

^{Shown above is a large adrenal cortical carcinoma resected from a 27-year-old woman. The tumor measured 17 cm in diameter and invaded kidney and spleen which necessitated en bloc removal of these organs with the tumor. The patient had evidence of virilization.}

Microscopic Pathology

On microscopic examination, the tumor usually displays sheets of atypical cells with some resemblance to the cells of the normal adrenal cortex. The presence of invasion and mitotic activity helps differentiate small cancers from adrenocortical adenomas.

The Weiss criteria are the most reliable histopathological scoring system differentiating ACC from adrenocortical adenoma.

ACC can be diagnosed by the presence of at least 3 of the 9 Weiss criteria:

• Nuclear grade III or IV
• More than 5 mitotic figures/50 HPF, counting 10 random fields in area of greatest number of mitotic figures on 5 slides with the greatest number of mitosis
• Presence of atypical mitotic figures (abnormal distribution of chromosomes or excessive number of mitotic spindles)
• Clear or vacuolated cells comprising 25% or less of tumor
• Diffuse architecture (more than 1/3 of tumor forms patternless sheets of cells; trabecular, cord, columnar, alveolar or nesting pattern is not considered to be diffuse)
• Microscopic necrosis
• Venous invasion (veins must have smooth muscles in wall; tumor cell clusters or sheets forming polypoid projections into vessel lumen or polypoid tumor thrombi covered by endothelial layer)
• Sinusoidal invasion (sinusoid is endothelial lined vessel in adrenal gland with little supportive tissue; consider only sinusoids within tumor)
• Capsular invasion (nests or cords of tumor extending into or through capsule with a stromal reaction); either incomplete or complete

Modified Weiss criteria (score of 3 or more suggests malignancy):

• Mitotic rate >5 per 50 high-power fields
• Cytoplasm (clear cells comprising 25% or less of the tumor)
• Abnormal mitoses
• Necrosis
• Capsular invasion

^{Micrograph of an adrenocortical carcinoma (left of image - dark blue) and the adrenal cortex it arose from (right-top of image - pink/light blue). Benign adrenal medulla is present (right-middle of image - gray/blue). H&E stain.}

Video

Shown below is a video explaining the histology of adrenocortical carcinoma

{{#ev:youtube|7jMFENhPaOM}}